Discover and read the best of Twitter Threads about #CALGB140503
Most recents (1)
#WCLC22 Highlights #CommunityOncology perspective:
1. #YESS Study - @RachM_UoN
2. #IMPower010 Update
3. #CALGB140503 - Sublobar resection
4. #SHAWL Study - @NarjustFlorezMD @jillfeldman4
5. #NADIM2 Trial by @MARIANOPROVENCI
1/6
#LCSM #MedTwitter @OncoAlert #OncEd @IASLC
1. #YESS Study - @RachM_UoN
2. #IMPower010 Update
3. #CALGB140503 - Sublobar resection
4. #SHAWL Study - @NarjustFlorezMD @jillfeldman4
5. #NADIM2 Trial by @MARIANOPROVENCI
1/6
#LCSM #MedTwitter @OncoAlert #OncEd @IASLC
1. #YESS Study @RachM_UoN: Lung CA screening with smoking cessation intervention concurrently:
- Smoking cessation is one of the most effective way to reduce lung CA mortality
- 33% quit at 3 months
- Women more likely to benefit
2/6
- Smoking cessation is one of the most effective way to reduce lung CA mortality
- 33% quit at 3 months
- Women more likely to benefit
2/6
2. #IMPower010 Update: Atezo has been approved for adjuvant NSCLC, Stg II - IIIA post surgery and chemo.
- mFU: 46mos
- OS trend for stage II-IIIA PDL1≥1% (HR 0.71)
- BUT, meaningful OS with PDL1≥50% (HR 0.42)
3/6
- mFU: 46mos
- OS trend for stage II-IIIA PDL1≥1% (HR 0.71)
- BUT, meaningful OS with PDL1≥50% (HR 0.42)
3/6
